Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Magnetic Resonance Imaging01:24

Magnetic Resonance Imaging

10.3K
Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...
10.3K
Imaging Studies for Cardiovascular System IV: CMRI01:21

Imaging Studies for Cardiovascular System IV: CMRI

511
Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative evaluation for small molecule somatostatin 4 receptor agonists: <i>in silico</i>, <i>in vitro</i>, and <i>in vivo</i> approaches.

Frontiers in pharmacology·2026
Same author

A Comparison of the Tofts and Linear Reference Region Models for DCE MRI When Monitoring Vascular Disruption in a Preclinical Tumor Model.

NMR in biomedicine·2026
Same author

Evaluations of Oxygenation and Vascular Perfusion in Pre-Clinical Models of Cancer and Wound Healing Using OS-DCE OAI.

Journal of visualized experiments : JoVE·2026
Same author

Dynamic Contrast Enhanced-Magnetic Resonance Fingerprinting (DCE-MRF) Improves Detection of Induced Vascular Perfusion Reduction in a Mouse Breast Cancer Model.

Magnetic resonance in medicine·2026
Same author

Investigating the oxygen dependence of FLASH-RT using electron paramagnetic resonance imaging.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Multiparametric MRI to Predict Response to Irreversible Electroporation Plus Anti-PD-1 Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Magnetic resonance in medicine·2025

Related Experiment Video

Updated: Mar 22, 2026

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

15.5K

A biomarker-responsive T2ex MRI contrast agent.

Iman Daryaei1, Edward A Randtke2, Mark D Pagel1,2

  • 1Department of Chemistry and Biochemistry, University of Arizona.

Magnetic Resonance in Medicine
|April 20, 2016
PubMed
Summary
This summary is machine-generated.

This study introduces a novel responsive MRI contrast agent that changes T2 exchange properties upon biomarker interaction. This new T2ex agent offers enhanced sensitivity and specificity for molecular imaging applications.

Keywords:
T2ex MRIchemical exchange: molecular imagingnitric oxideresponsive agent

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration
05:30

Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration

Published on: May 19, 2023

1.9K

Related Experiment Videos

Last Updated: Mar 22, 2026

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

15.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration
05:30

Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration

Published on: May 19, 2023

1.9K

Area of Science:

  • Magnetic Resonance Imaging (MRI)
  • Molecular Imaging
  • Contrast Agents

Background:

  • Responsive MRI contrast agents offer potential for enhanced molecular imaging.
  • Traditional agents lack specificity and sensitivity for certain biomarkers.
  • T2 exchange (T2ex) properties are key to developing new responsive agents.

Purpose of the Study:

  • To investigate a novel responsive MRI contrast agent.
  • To evaluate its ability to alter T2ex properties upon biomarker interaction.
  • To assess its potential for molecular imaging.

Main Methods:

  • The contrast agent Tm-DO3A-oAA was reacted with nitric oxide (NO) and O2.
  • R1 and R2 relaxation rates were measured across varying concentrations, temperatures, and pH.
  • Chemical exchange saturation transfer (CEST) spectra were acquired using a 7 Tesla MRI scanner.

Main Results:

  • Reaction with NO and O2 increased the agent's r2 relaxivity 6.4-fold, while r1 relaxivity remained unchanged.
  • This confirmed Tm-DO3A-oAA as a responsive T2ex agent.
  • Ligand differences (benzimidazole vs. ortho-aminoanilide) explained the observed fast vs. slow chemical exchange rates.

Conclusions:

  • T2ex MRI contrast agents represent a new class of responsive agents.
  • These agents exhibit high detection sensitivity and specificity for biomarkers.
  • They serve as a valuable new tool for molecular imaging.